ICON Plc to Unveil Q2 2024 Financial Results
ICON Plc Schedules Second Quarter 2024 Earnings Conference Call
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on
Should Weakness in ICON Public Limited Company's (NASDAQ:ICLR) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
ICON (NASDAQ:ICLR) has had a rough three months with its share price down 6.8%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean t
Is Icon PLC (ICLR) a Solid Growth Stock? 3 Reasons to Think "Yes"
Barclays Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $355
Barclays analyst Luke Sergott maintains $Icon PLC(ICLR.US)$ with a buy rating, and maintains the target price at $355.According to TipRanks data, the analyst has a success rate of 40.5% and a total av
Here's Why Icon PLC (ICLR) Is a Strong Momentum Stock
Why Icon PLC (ICLR) Is a Top Growth Stock for the Long-Term
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,400 Today
Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.88% on an annualized basis producing an average annual return of 19.66%. Currently, Icon has a market capitalization of $26.3
Here's Why ICON (NASDAQ:ICLR) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Is Now The Time To Put ICON (NASDAQ:ICLR) On Your Watchlist?
Global Cardiovascular Clinical Trials Market Size To Exceed USD 9.76 Billion By 2033 L a CAGR of 6.18%
Icon PLC | 6-K: Report of foreign private issuer (related to financial reporting)
Icon Initiated at Buy by Goldman Sachs
Icon Initiated at Buy by Goldman Sachs
Goldman Sachs Initiates Coverage On Icon With Buy Rating, Announces Price Target of $370
Goldman Sachs analyst Matthew Sykes initiates coverage on Icon (NASDAQ:ICLR) with a Buy rating and announces Price Target of $370.
Goldman Sachs Initiates Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $370
Goldman Sachs analyst Matthew Sykes initiates coverage on $Icon PLC(ICLR.US)$ with a buy rating, and sets the target price at $370.According to TipRanks data, the analyst has a success rate of 49.6% a
Form 144 | Icon PLC(ICLR.US) Officer Proposes to Sell 1.6 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 5, $Icon PLC(ICLR.US)$ Officer DIARMAID CUNNINGHAM intends to sell 4,877 shares of its common stock on Jun 5, with a total market value of approximately $1.6 million. DIA
Form 144 | Icon PLC(ICLR.US) Director Proposes to Sell 1.52 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 5, $Icon PLC(ICLR.US)$ Director White Poplar Limited intends to sell 6,764 shares of its common stock on Jun 5, with a total market value of approximately $1.52 million.
Icon PLC (ICLR) Is an Incredible Growth Stock: 3 Reasons Why
Icon PLC (ICLR) Upgraded to Buy: Here's What You Should Know
ICON Plc to Present at the Jefferies Global Healthcare Conference
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on